Cardiovascular

Main Content

INVESTED

Purpose

This study is looking at whether one type of approved influenza vaccine will reduce cardiovascular and pulmonary problems more than another type of approved influenza vaccine in patients who have had a heart attack or heart failure.

  • Principal Investigator: Robert C. Long, MD, PharmD

Who can participate

Those eligible to participate in this study include:

  • Adults 18 years of age
    • who have had a heart attack or heart failure
    • Able to receive the influenza vaccine

For more information

  • Theresa Hickey Hutson
    University of Mississippi Medical Center
    Division of Cardiology
    2500 N. State St.
    Jackson, MS 39216
    (601) 815-8702
  • IRB Number: 2017-0215